Comparison
Maridebart Cafraglutide vs. Mazdutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
2259884-03-0
Molecular weight
no data
4790 g/mol
Half-life
no data
132 h
Sequence
no data
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit FettsäureseitenketteMechanism of action
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
4
of which in humans
1
4
Effects recorded
2
4
Open conflicts
0
0
Documented adverse events
1
0
Legal status
Full entries
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Mazdutide?
- Maridebart Cafraglutide is classified as "Metabolic", while Mazdutide is classified as "Metabolic". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Mazdutide?
- The highest available evidence level is "Human RCT" for Maridebart Cafraglutide and "Human RCT" for Mazdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Mazdutide in Germany and the United States?
- Germany: Maridebart Cafraglutide — Unapproved, Mazdutide — Research only. United States: Maridebart Cafraglutide — Unapproved, Mazdutide — Research only. These are factual summaries with source and review date on the individual pages.